Cancer treatment to undergo paradigm shift in future

Published: 06th June 2013 11:23 AM  |   Last Updated: 06th June 2013 11:23 AM   |  A+A-

According to scientists, in the future, cancer will be treated not as an organ-specific disease but will depend on understanding the genes that work defectively and lead to cancer.

“Drugs are developed around targets (genetic/protein pathways) and generally not around specific organs. There is increasing anecdotal evidence that actionable mutations found in cancers suggest repurposing drugs that have hitherto not been used to treat cancers of the tissue of origin,” says Dr Vijay Chandru, chairman and CEO of Strand Life Sciences.

Thus, clinical strategy may need to go beyond the obvious, he points out.

Dr Kalyanasundaram Subramanian, their chief scientific officer adds, “Another parallel here is with HIV, where usually a cocktail of drugs are used to treat the disease. Similarly, in cancer it is likely that in the future, treatment will be multi-pronged by attacking the cancer on various fronts based upon the mutation profile.”

Do Indian scientists agree with the shift in thought? Dr Chandru says, “Yes, particularly since our ability to find these mutations and match them to therapeutic strategies is growing by leaps and bounds. Advances in technology of genome sequencing and rapid reduction in costs are primary drivers.”

Cancer is a scary disease and the costs of treatment can be debilitating for individuals and society, he says. It is estimated, for example, that less than 10 per cent of patients who receive chemotherapy for lung cancer benefit, while administration of other anti-cancer agents that may benefit them are delayed, he explains.

Can genetic diseases like diabetes benefit from the above strategies and what will the future be like? Dr Chandru thinks, “Pharmacogenomics (dosage sensitivity, adverse reactions, etc) will likely extend broadly to other disease areas.

Certain subtypes of diabetes can also benefit from diagnosis of mutations in the genome.” Leading neuroscientists have suggested that subtyping diseases may be the future and often use the analogy with cancer, he says.

Dr Subramanian, on the other hand, thinks, “I will go even further and say that in the not-so-distant future every disease will be addressed this way and every patient will be treated in a personalised manner for every disease.”

Dr Ryan B Jensen, assistant professor of therapeutic radiology at Yale School of Medicine, New Haven in Connecticut, USA, says, “The future of cancer research is mostly going to be understanding the unique combination of genes that are mutated in each type of cancer and developing drugs that specifically target these genetic pathways instead of specific organs.”

This will move clinicians away from categorising cancer as organ specific and instead, a lung tumour may have the same genetic mutations as a colon tumour and treated with the same drug, he explains.

The current standard of care is to treat cancer in an organ-centric manner and hence breast cancer is treated differently when compared to lung or colon cancer, he adds.

Stay up to date on all the latest Bengaluru news with The New Indian Express App. Download now


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp